Endo Unit Loses Trial To Stop Launch Of Vasostrict Generic
After a three-day bench trial, Delaware's chief federal judge ruled Tuesday that an Endo International unit could not stop the launch of a generic version of blood pressure medication Vasostrict because...To view the full article, register now.
Already a subscriber? Click here to view full article